
The popularity of Novo Nordisk’s (NVO) weight-loss drug, Wegovy, has already catapulted its stock to become Europe’s most valuable company, as measured by market capitalization.
Wegovy is a GLP-1 drug. Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used to treat type 2 diabetes and obesity. They mimic the action of GLP-1, a hormone released by the stomach after eating that signals the pancreas to produce more insulin and keep blood sugar levels normal.